Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

at could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than we or others do, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 27, 2014  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Morgan Stanley Global Healthcare Conference on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded ... after conclusion of the live event and accessible at ...
(Date:8/27/2014)... 2014 North American lighting leader OSRAM SYLVANIA ... for the new OSRAM ITOS ® PHASER ® ... for microscopy, endoscopy and surgical head lamps that delivers the ... and lamp life. "We,re honored to be recognized ... innovative new technologies of the past year," said Andreas ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... agents and light to kill tissue) appears to better ... by sun damage) at three months after treatment than ... , Author: Gayatri Patel, M.D., M.P.H., of the ... colleagues. , Background: AKs are rough, scaly ... fair complexions who have had lots of sun exposure. ...
(Date:8/27/2014)... 2014 BRIC Laparoscopes Market Outlook to ... key market data on the BRIC Laparoscopes market. The ... (in units) and average prices (in US dollars) within ... Flexible Tip Video Laparoscopes), Robotic Surgical Systems and Rigid ... advantages to the patient with laparoscopic surgery versus the ...
(Date:8/27/2014)... are known to play a key role in inflaming ... atherosclerosis. A new study at UCLA demonstrates that they ... disease that narrows the small blood vessels in the ... that a peptide mimicking part of the main protein ... help reduce the production of oxidized lipids in pulmonary ...
(Date:8/27/2014)... August 27, 2014 Dr. Stewart ... Center see multitudes of patients suffering from impaired vision. ... Cataract vision correction surgery . Recently, Dr. Shofner ... information during an eye exam and also online. To ... top five myths about glaucoma. , 1)    Myth: People with ...
(Date:8/27/2014)... The federal judge overseeing thousands of ... the deadline for plaintiffs to enroll in the U.S. ... by U.S. District Judge David Katz of the Northern ... DePuy ASR Settlement Program must do so by September ... Implant Products Liability Litigation – MDL 2197) , “Our ...
Breaking Medicine News(10 mins):Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3
... without obesity , TUESDAY, April 13 (HealthDay News) -- A ... insulin work together in the brain to control blood sugar ... , The findings also appear to suggest that diabetes and ... many physicians, think you develop diabetes that is solely secondary ...
... Prostate cancer will ... the African American community), making it the most common cancer among American men. Join the ... Prostate Cancer. , ... (PRWEB) April 13, 2010 -- Registration is now open for Little Red Door’s Unite 2 ...
... ... through Community , ... (PRWEB) April 13, 2010 -- Motivational Speaker/MS Advocate and Author Erin Morrow Still released ... Sclerosis. , , ,Published by iUniverse with a forward by Harold Moses Jr. ...
... have no social fear and appear open, friendly to ... -- Children with a rare condition called Williams ... racial prejudice, a new study shows. , The finding ... of racial stereotyping. , French and German researchers examined ...
... Finding underscores the need to treat Alzheimer,s patients ... 13 (HealthDay News) -- People with memory loss can ... a new study has found. , University of Iowa ... five patients with memory loss. The patients couldn,t remember ...
... Fifty-eight percent of Americans (96 percent of Republicans, 10 ... repealing the health care reform legislation that was signed ... to a new national survey conducted April 6 - ... Policy and Professionalism Research (CHPPR). Americans 18 ...
Cached Medicine News:Health News:Hormones Tied to Diabetes Might Also Influence Fertility 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 3Health News:Kids With Rare Condition Lack Racial Prejudice 2Health News:Even As Memory Fades, Emotions Linger 2Health News:Health care reform 'important' even to those who want new law repealed 2
Puros allografts is a family of bone products specially designed and processed to meet the demanding needs of spine surgeons. The grafts are processed using the proprietary Tutoplast process....
... Graftech cervical dowels are ... to graft expulsion and improve ... allows immediate red blood cell ... Grafton DBM gel into the ...
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: